Walgreens teams up with Verily to tackle chronic conditions

Amy Baxter | | Health Exec | Precision Medicine

Walgreens Boots Alliance has teamed up with Verily, the life sciences unit of Google parent company Alphabet. The two companies will focus on improving outcomes for patients with chronic conditions, CNBC reported.

The partnership will deploy Verily’s technology at Walgreens’ pharmacies and specifically focus on medication adherence, an issue that costs the healthcare system about $100 billion to $289 billion annually.

The partnership may help Walgreens connect more technology to its growing healthcare services and could signal a move to fend off competitors like CVS Health, which recently acquired health insurance provider Aetna, and Amazon, which has continued to step into the pharmacy and healthcare space.

See the full story below:

Walgreens to tackle health-care costs with Alphabet’s Verily

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.